Cargando…

NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS

In light chain amyloidosis, a reduction in dFLC to below 40 mg/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac am...

Descripción completa

Detalles Bibliográficos
Autores principales: Idowu, Abiodun, Tung, Lillian, Chu, Catherine, Skeete, Jamario, Paner, Agne, Okwuosa, Tochukwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035620/
https://www.ncbi.nlm.nih.gov/pubmed/36970162
http://dx.doi.org/10.12890/2023_003768
Descripción
Sumario:In light chain amyloidosis, a reduction in dFLC to below 40 mg/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac amyloidosis despite a post-treatment reduction in dFLC to <10 mg/l. LEARNING POINTS: Patients with light chain (AL) amyloidosis may develop new cardiac involvement despite achieving haematological remission. In patients with AL amyloidosis, a very good partial haematological response (dFLC <10 mg/l) does not obviate the need for regular cardiac monitoring.